

1 **FULL TITLE**

2 **Effectiveness of integrating cervical cancer prevention strategies into HIV care**
3 **programmes: A mixed-methods systematic review protocol.**

4 **SHORT TITLE**

5 **Integrating cervical cancer prevention strategies and HIV care services.**

6

7 Kimeshnee Govindsamy^{1,2*}, Susanne Noll², Ntombifuthi Blose³, Edina Amponsah-Dacosta²

8 ¹ Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine,
9 University of Cape Town, Western Cape, South Africa.

10 ² Vaccines for Africa Initiative (VACFA), Faculty of Health Sciences, School of Public
11 Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

12 ³ Health Systems Trust, Durban, South Africa

13 *Corresponding author

14 Email: GVNKIM019@myuct.ac.za

15

16 **Funding:** No financial support will be required for this review.

17 **Competing interests:** The authors have declared that no competing interests exist.

18 **Data availability:** No datasets will be generated or analysed for this systematic review
19 protocol. All relevant data from this study will be made available upon study completion.

20

21

22 **Abstract**

23 **Introduction**

24 Cervical cancer, which is the fourth most frequently diagnosed cancer among women
25 globally, remains a significant health burden despite being preventable and treatable,
26 exposing gaps in accessing prevention and control services. Adolescent girls and young
27 women (AGYW) face heightened risk of persistent HPV infection, a primary cause of
28 cervical cancer. The overlap of cervical cancer and HIV exacerbates public health challenges,
29 especially in resource-limited areas, urging intensified efforts in bolstering prevention and
30 control measures. Integrating HPV vaccination, cervical cancer screening, treatment of
31 precancerous lesions and educational interventions into HIV care programs shows promise in
32 effectively addressing this dual burden.

33 **Methods**

34 To evaluate the effectiveness of integrating cervical cancer prevention strategies within HIV
35 care programs, a mixed-methods systematic review will be conducted. A comprehensive
36 Boolean search for literature published between 2006 to present and indexed in PubMed,
37 Cochrane Library, EBSCO Host, Web of Science, Scopus, and Google Scholar will be
38 conducted, without imposing any language restrictions. This review will be conducted in
39 alignment with the Joanna Briggs guidelines on systematic reviews together with the
40 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
41 Data from eligible studies will be extracted and synthesized, and their quality assessed.

42

43

44 **Discussion**

45 There is limited understanding of the effectiveness of integrating cervical cancer prevention
46 and HIV care in the real-world setting. While some studies touch on integration, focus tends
47 to be on cervical cancer screening alone, neglecting vaccination, treatment of precancerous
48 lesions, and education programs. Previous reviews on this focus are outdated, surpassing six
49 years. This systematic review aims to fill these evidence gaps by thoroughly evaluating the
50 challenges and opportunities associated with integrating the full complement of HPV
51 prevention strategies and HIV care programs. The anticipated findings could enhance service
52 delivery models aimed at reducing cervical cancer incidence and mortality among AGYW
53 living with HIV.

54 **Trial registration**

55 Systematic review registration: PROSPERO registration number: CRD42024535821.

56

57

58

59

60

61

62

63

64

65 **Introduction**

66 **Background**

67 Cervical cancer ranks as the fourth most frequently diagnosed cancer among women globally,
68 with current global estimates from 2022 indicating that 660 000 women are diagnosed with
69 cervical cancer and 350 000 women die from this disease annually, according to the World
70 Health Organization (WHO) [1]. Persistent infection with the Human Papillomavirus (HPV)
71 following sexual transmission is the primary sufficient cause of cervical cancer [2].
72 Furthermore, cervical cancer is the most common HPV-related disease [2]. Most HPV
73 infections resolve spontaneously and do not cause symptomatic disease. However, persistent
74 infection with specific high-risk HPV types (most frequently HPV types 16 and 18) may lead
75 to pre-cancerous lesions and if untreated these lesions may progress to invasive cervical
76 cancer [2]. According to Okunade [2] approximately 99.7% of cervical cancer cases are
77 caused by persistent high-risk HPV infection. HPV is estimated to infect approximately 291
78 million women globally, with a significantly higher prevalence among women under the age
79 of 25 years [3].

80 There are significant disparities in the prevalence of cervical cancer globally which highlights
81 variations in accessibility, coverage, and quality of preventative and control measures as well
82 as the prevalence of risk factors for cervical cancer. More than 85% of cervical cancer cases
83 and deaths occur in low- and middle-income countries (LMICs) where these measures are
84 suboptimal whilst the prevalence of risk factors are usually higher [4]. This inequality gap
85 continues to widen, as substantial declines in cervical cancer incidence rates have been
86 observed in high-income countries (HICs) with some nations even forecasted to be
87 progressing toward the goal of cervical cancer elimination in the coming decades [5]. This
88 can be attributed to the effectiveness of routine cervical cancer prevention programs in these

89 regions. In contrast, in certain sub-Saharan African regions and in several European and
90 western Asian countries, rates have either increased or remained relatively stable at elevated
91 levels [5]. This is attributed to the suboptimal provision and utilization of prevention
92 programs in these settings.

93 Although HPV is the underlying sufficient cause of cervical cancer there are other risk factors
94 associated with this disease which include smoking, increased parity, long-term use of oral
95 contraceptives as well as infection with human immunodeficiency virus (HIV) [2]. Studies
96 have shown that women who are HIV-positive face a six-fold increased risk of developing
97 cervical cancer compared to those without HIV, which further exacerbates the burden of
98 cervical cancer [5]. This heightened risk stems from a multifaceted interplay of biological and
99 societal factors. Among these are the direct impact of HIV on the immune regulation of HPV,
100 accelerated disease advancement in HIV-positive women, extended life expectancy due to
101 antiretroviral therapy, and obstacles such as stigma, poverty, and gender-related barriers that
102 hinder women from accessing timely care [4]. Compelling evidence indicates that women
103 infected with HIV face an elevated risk of persistent infection with multiple types of HPV at
104 an early age, specifically between the ages of 13 and 18 years, which contributes to an
105 increased likelihood of developing cervical cancer at a younger age [3]. This dual burden of
106 HPV and HIV poses a complex challenge to healthcare systems worldwide, especially among
107 adolescent girls and young women (AGYW) living with HIV.

108 Cervical cancer can be prevented, treated, and ultimately eliminated as a public health
109 concern through primary, secondary, and tertiary prevention measures. These prevention
110 strategies differ among females living without and with HIV as outlined in Fig 1, as per the
111 WHO guidelines [6]. Primary prevention measures include HPV vaccination and educational
112 interventions that create awareness related to cervical cancer risks and prevention and control

113 strategies. Secondary prevention includes cervical cancer screening and treatment of
114 precancerous lesions. Tertiary prevention includes the treatment of invasive cancer.

115

116 **Fig 1. Summary of cervical cancer prevention strategies as per WHO guidelines [6].**

117

118 **Primary prevention**

119 Prophylactic HPV vaccination has been regarded as the most effective long-term strategy for
120 preventing HPV infection, cervical cancer and other cancers associated with HPV [4]. HPV
121 vaccines are most effective if administered prior to HPV-exposure and therefore is primarily
122 targeted to adolescent girls (9-14 years of age), prior to sexual debut [7]. The first HPV
123 vaccine was licensed in 2006 and currently there are six licensed prophylactic vaccines
124 available, all of which are recommended for global use by the WHO [7]. These include three
125 bivalent vaccines, two quadrivalent vaccines and one nonvalent vaccine [4]. HPV vaccines
126 are designed to prevent over 95% of HPV infections caused by the common high-risk HPV
127 types 16 and 18 as well as some cross protection against other less common HPV types that
128 can cause cervical cancer [1]. Vaccination is a powerful preventative strategy as it targets the
129 underlying cause and moreover widespread vaccination creates herd immunity, benefiting
130 even those who cannot receive vaccines. According to WHO recommendations, females aged
131 9-20 years should receive one- or two-dose schedules and females 21 years and older should
132 receive two-doses with a six- month interval [7]. Females living with HIV at all ages should
133 receive three doses (or two doses if feasible) [7]. The high prevalence of HPV infections in
134 HIV positive females emphasizes how important it is to vaccinate this population. HPV
135 vaccines are a safe and effective tool that when combined with other cervical cancer

136 prevention strategies can significantly reduce the incidence of cervical cancer and its
137 associated mortality.

138 Educational interventions encompass health education initiatives that are designed to enhance
139 an individual's understanding and awareness of health-related matters, in this instance
140 matters relating to cervical cancer prevention strategies, which ultimately would lead to a
141 positive change in their behaviour [8]. These interventions play a crucial role in creating
142 awareness and imparting knowledge on the importance of cervical cancer prevention
143 strategies and risks. In addition, sexual and reproductive education, tailored to age and
144 culture, that promotes safer sexual practices also aids in creating awareness and potential
145 behavioural changes. In providing the necessary information females are empowered to make
146 informed decisions about their health, seek HPV vaccination services and timely screening,
147 as well as adopt proactive measures and ultimately reduce their risk of developing cervical
148 cancer.

149 **Secondary prevention**

150 To prevent cervical cancer females can undergo various cervical screening tests to detect
151 precancerous cells and thereafter receive the appropriate pre-treatment to reduce the risk of
152 progression to invasive cervical cancer. The conventional approach for screening involves
153 cytology screening (conventional or liquid based), commonly known as Papanicolaou (Pap)
154 test or pap smear [9]. Positive cytology results lead to confirmation through colposcopy, and
155 subsequent biopsies of suspicious lesions for histologically confirmed diagnosis [9]. Over the
156 past 15 years, additional screening strategies have been introduced including visual
157 inspection with acetic acid (VIA) and molecular tests such as high-risk HPV DNA testing [9].
158 In 2021 the WHO recommended HPV-DNA detection as the primary screening method
159 particularly for females living with HIV [6]. The WHO identifies females living without HIV

160 in the age group 30-49 years as a priority for screening and should be screened every five to
161 ten years with a pap smear, VIA technique or HPV-DNA testing [6]. For females living with
162 HIV, those aged 25-49 years are identified as a priority group and should be screened every
163 three to five years preferably with HPV-DNA testing or other screening tests as available [6].
164 After the age of 50 years the WHO suggests screening is stopped after two consecutive
165 negative screening results in females living with and without HIV [6]. More recently newer
166 techniques have been developed: other molecular tests such as those relying on HPV
167 messenger ribonucleic acid (mRNA), oncoprotein detection or DNA methylation; more
168 objective assessments conducted on cytological samples such as p16/Ki67 dual staining; and
169 enhanced visual inspection tests utilizing artificial intelligence/ machine learning platforms
170 such as automated visual evaluation of digital images [6].

171 In resource-limited settings, the predominant approach for treatment of cervical abnormalities
172 is tissue ablation techniques such as cryotherapy or thermal ablation [10]. Ideally, if the
173 patient qualifies for ablative treatment, it should be performed immediately during the same
174 visit as the positive screening test (single-visit approach). However, at times this may not be
175 feasible in some healthcare facilities and therefore a second visit is required (multiple-visit
176 approach). For women who are not eligible for ablation or in HICs the main approach for
177 treatment involves the excision of histologically confirmed cervical abnormalities [10].
178 Excisional treatment options include loop electrosurgical excision (LEEP), large loop
179 excision of the transformation zone (LLETZ) or cone excision [10].

180 The WHO recommends two approaches to screening and treatment namely, the “screen-and-
181 treat” and the “screen, triage and treat” approach [6]. In the “screen-and-treat” approach
182 treatment is administered to females solely based on a positive primary screening test (which
183 means there is no secondary screening test and no histopathological diagnosis) [6]. In the
184 “screen, triage and treat” approach the treatment decision is based on a positive result from

185 the initial screening test, followed by a positive outcome in a subsequent test (referred to as a
186 “triage” test), with or without histologically confirmed diagnosis [6]. For females in the
187 general population, the WHO recommends HPV DNA detection as the screening method in a
188 “screen-and-treat” or “screen, triage and treat” approach starting at the age of 30 years with
189 regular screening every five to ten years [6]. For females living with HIV, it is recommended
190 that HPV DNA detection be used in a “screen, triage and treat” approach only starting at the
191 age of 25 years with regular screening every three to five years [6].

192 Despite the development and implementation of cervical cancer prevention strategies this
193 disease continues to be a public health concern, particularly in LMICs. As a result of this in
194 2020 the WHO introduced a “global strategy” to accelerate the elimination of cervical cancer
195 [6]. This strategy proposes the following targets: 90% of adolescent girls globally should be
196 vaccinated against HPV; 70% of women should undergo HPV screening and 90% of women
197 diagnosed with cervical cancer should receive suitable follow-up treatment [6]. The aim of
198 this global strategy is to reduce the incidence of cervical cancer to below a threshold of 4
199 cases per 100 000 women-years in every country [11]. Meeting these objectives set out by the
200 WHO requires reconsideration of existing strategies to accelerate the adoption of HPV
201 vaccination, cervical cancer screening and timely treatment of precancerous lesions, whilst
202 optimizing rational resource allocation and use. The WHO advocates for the integration of
203 these prevention strategies in other healthcare systems to further enhance its effectiveness
204 [12].

205 There has been a growing interest in integrating cervical cancer prevention strategies into
206 HIV care programs [13]. Such integration can potentially improve access to cervical cancer
207 screening, early detection, and pre-treatment services for AGYW living with HIV.
208 Additionally, it may offer opportunities for the efficient utilization of established healthcare
209 resources and strengthen the health system’s capacity to address both HIV and cervical

210 cancer. Integrated healthcare approaches aim to leverage existing HIV care infrastructure to
211 provide cervical cancer preventative services, which can encompass the full complement of
212 prevention strategies. The integration not only streamlines healthcare delivery but also
213 capitalizes on the regular contact that AGYW living with HIV have with healthcare
214 providers. Supporting evidence highlighting the feasibility and outcomes of such integration
215 programs has been published. For instance, Mwanahamuntu *et al.*, [14] conducted a study on
216 the integration of cervical cancer prevention services into HIV care services in Zambia and
217 reported that over the course of 2.5 years more than 20 000 women had undergone cervical
218 cancer screening following integration. Furthermore, studies conducted in Kenya,
219 Mozambique and Botswana have reported cervical cancer screening within HIV care services
220 to be feasible, acceptable, and effective [15–17].

221 Despite the potential benefits of integrating cervical cancer prevention and HIV care, there is
222 still a limited understanding of its effectiveness in the real-world setting. As such, it is
223 important to systematically assess the effectiveness of integrating such programs across
224 various contexts.

225 This systematic review seeks to comprehensively assess existing evidence, by employing a
226 mixed methods approach, to provide a holistic understanding of the outcomes and
227 implications of integrating cervical cancer prevention strategies into HIV care programs. This
228 review will delve into the uptake of HPV vaccination, cervical cancer screening,
229 precancerous treatment, and educational interventions aimed at enhancing personal urgency
230 and positive behavioural change. In addition, we will describe the knowledge, awareness, and
231 willingness of AGYW living with HIV with regards to utilizing and adhering to these
232 strategies following integration into existing HIV care programs. Given the increasing global
233 burden of cervical cancer, the continued burden of HIV, and the increased risk of HPV
234 infections in AGYW living with HIV, this review will hold significant relevance and urgency

235 for public health initiatives aimed at improving the health and well-being of AGYW living
236 with HIV as well as reducing the incidence and mortality rates of cervical cancer.

237

238 **Rationale for the review**

239 Cervical cancer is the fourth most common cancer among women globally, despite it being a
240 preventable and curable health issue through universal access to effective cervical cancer
241 prevention and control programs. AGYW living with HIV are a population of particular
242 concern as they are at an increased risk of persistent infection with multiple types of HPV.
243 The co-occurrence of cervical cancer and HIV represents a significant public health
244 challenge, particularly in resource-limited settings and requires more effort to be placed on
245 improving current cervical cancer prevention and control measures. Cervical cancer
246 prevention strategies should encompass multidisciplinary approaches that include HPV
247 vaccination, screening, precancerous treatment, and educational interventions. Utilising
248 existing HIV care programmes as a means of integrating cervical cancer prevention strategies
249 into HIV routine care provides an effective way for improving cervical cancer prevention for
250 the most at-risk population and should be prioritised. Existing literature primarily focuses on
251 isolated aspects of either HIV care or cervical cancer prevention, or some but not all
252 preventative strategies, thus leaving a fragmented understanding of the holistic benefits of
253 integrating these public health concerns. Studies have considered integration of these
254 programs [15–17], although, more focus is placed on cervical cancer screening as a
255 prevention strategy as opposed to comprehensive approach that includes vaccination,
256 education, and pre-treatment. Moreover, the search end dates of these reviews are outdated -,
257 being more than six years old- and do not consider recent recommendations and
258 advancements in the field. This review aims to provide a comprehensive assessment of the

259 effectiveness, knowledge, awareness, and willingness among AGYW living with HIV,
260 related to integrating cervical cancer prevention strategies, which includes vaccination,
261 screening, precancerous treatment, and educational interventions, into existing HIV care
262 programs. A mixed methods systematic review is an ideal research design for this study as it
263 allows for an overall examination of both quantitative and qualitative data. The quantitative
264 evidence will provide insights into the effectiveness of the integration strategy, whilst the
265 qualitative evidence can shed light on the knowledge, awareness, and willingness of AGYW
266 living with HIV. Findings from this review will have the potential to reform current policy
267 and practice, thereby contributing to improving health outcomes for AGYW living with HIV
268 and reduce cervical cancer incidence and mortality.

269

270 **Research aims and objectives**

271 **Aim**

272 To describe the effectiveness of integrating cervical cancer prevention strategies into existing
273 HIV care programs.

274 **Objectives**

- 275 1. To identify and describe integration models for cervical cancer prevention strategies
276 and HIV care programs.
- 277 2. To assess the effectiveness of integrating cervical cancer prevention strategies into
278 existing HIV care programs.

279 2.1 To assess the uptake of HPV vaccination, cervical cancer screening, precancerous
280 treatment, and educational interventions among AGYW living with HIV
281 following integration into existing HIV care programs.

282 2.2 To assess the knowledge, awareness, and willingness of AGYW living with HIV
283 to utilise and adhere to cervical cancer prevention strategies following integration
284 into existing HIV care programs.

285

286 **Methods**

287 A comprehensive mixed methods review that evaluates primary studies employing
288 qualitative, quantitative, and mixed methods will be conducted in alignment with the Joanna
289 Briggs guidelines on mixed methods systematic reviews together with the Preferred
290 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18,19].
291 The protocol for this review was developed in accordance with the PRISMA-Protocol
292 (PRISMA-P) guidelines and checklist (S1 Checklist. PRISMA-P 2015 checklist.) and is
293 registered with the International Prospective Register of Systematic Reviews (PROSPERO)
294 (ID: CRD42024535821), any changes to the published record will be reported [20]. The
295 proposed timeline for this review is February 2024 to February 2025.

296

297

298

299 **Eligibility Criteria**

300 **Inclusion Criteria**

- 301 1. All primary research studies (including those with quantitative, qualitative, and mixed
302 methods research designs) reporting findings on the effectiveness, knowledge,
303 awareness, and willingness related to integrating cervical cancer prevention strategies
304 (vaccination, education, screening, treatment of precancerous lesions, and educational
305 interventions) into existing HIV care services will be considered. This includes all
306 observational studies (cross-sectional and cohort), interventional studies (single-arm
307 intervention studies, randomised control trials, cluster randomised control trials,
308 cross-over trials, and non-randomised control trials) and qualitative studies
309 (interviews, surveys, focus groups, ethnography, phenomenology, grounded theory
310 studies and qualitative process evaluations).
- 311 2. The target population for this review are AGYW living with HIV, which according to
312 the WHO are females aged between 9 and 25 years of age. Therefore, only studies
313 that include females within this age group living with HIV will be included.
- 314 3. Only studies published after 2006 will be considered, since the first commercially
315 available prophylactic HPV vaccine was approved in this year.
- 316 4. This systematic review has global significance that aims to address universal
317 challenges affecting cervical cancer research on a global scale and therefore there will
318 be no geographical limits placed on search strategy.
- 319 5. We will not enforce any limitations on the language of publication. Instead, we will
320 facilitate the translation of any potentially relevant publications into English to ensure
321 their inclusion in the selection process and facilitate data extraction.

322

323 **Exclusion criteria**

- 324 1. Studies that exclusively focus on AGYW living without HIV or that do not clearly
325 specify the age and HIV status of the study participants will be excluded as this
326 review focuses primarily on AGYW living with HIV.
- 327 2. Studies that include females younger than 9 or older than 25 years of age as this does
328 not align with the target population for this review.
- 329 3. Studies that evaluate the integration of cervical cancer prevention strategies into
330 programs other than HIV care services will not be considered.
- 331 4. Studies published prior to 2006 will be excluded from this review as prophylactic
332 HPV vaccines were not approved or commercially available at the time.
- 333 5. This review will exclude all other review studies, modelling studies, evidence
334 synthesis studies, case studies, case series, case reports and conference proceedings.

335

336 **Outcomes**

- 337 1. A description of models used to integrate cervical cancer prevention strategies with
338 existing HIV care programs will be identified and described.
- 339 2. The effectiveness of integrating cervical cancer prevention strategies into existing
340 HIV care programs will be assessed in terms of the following outcomes:
- 341 2.1 The uptake of HPV vaccination, cervical cancer screening, precancerous
342 treatment, and educational interventions by AGYW living with HIV following
343 integration.
- 344 2.2 The knowledge, awareness, and willingness of AGYW living with HIV to utilise
345 and adhere to cervical cancer prevention strategies following integration.

346 **Search strategy**

347 A search strategy will be developed by one of the authors (KG) together with an information
348 specialist (SN). A comprehensive literature search will be performed to enable capturing of as
349 many relevant articles as possible based on the inclusion and exclusion criteria outlined. The
350 following online electronic databases will be searched: PubMed, Cochrane Central Library,
351 EBSCO Host (Academic Search Premier, Africa-Wide Information, Cumulative Index to
352 Nursing and Allied Health Literature [CINAHL], Health Source - Consumer Edition, Health
353 Source: Nursing/Academic Edition, APA PsycArticles, APA PsycInfo), Web of Science,
354 Scopus, and Google Scholar. Key words, medical subject headings (MeSH) and text words
355 related to the themes; cervical cancer, HIV, prevention strategies and integration will be
356 developed and then combined in the search strategy using Boolean operators, after which
357 eligible articles will be identified. The search will be modified and applied to each electronic
358 database (S1 Appendix. Database literature search strategy.). A standardized report template
359 that will aid in keeping a record of all electronic databases searched, the search terms used
360 and the total count of search results for each database will be developed and maintained.
361 Reference lists of relevant studies will be searched for further articles in case they were
362 missed during the primary searches. No geographical or language limitations will be applied.

363

364 **Study selection**

365 All publications identified from the electronic database searches will be downloaded into a
366 reference manager program, Zotero [21], and imported into a web-based platform called
367 Rayyan for deduplication and screening [22]. Two authors (KG and NB) will independently
368 screen articles by title and abstract and then full text articles screened for inclusion against

369 the eligibility criteria. Reasons for exclusion of full text studies that do not meet the inclusion
370 criteria will be recorded and reported in a table. Where the same study, using the same
371 sample and methods, has been presented in different reports, we will collate these reports so
372 that each study (rather than each report) is the unit of interest in our review to avoid over
373 representation of datasets in each study in the systematic review results. Oversight of the
374 study selection process will be provided by a third author (EA-D). Any disagreements that
375 arise between the two authors (KG and NB) at any stage of the study selection process will be
376 resolved through discussion and will involve a third author (EA-D) if necessary. A PRISMA
377 flow diagram will be used to present the selection process and results of the search [19].

378

379 **Data extraction and management**

380 Data extraction will be performed using piloted extraction forms by two authors (KG and
381 NB) to ensure consistency across included studies. Standardised data extraction forms will be
382 designed using Microsoft excel file (Version 2402) and used to record extracted data from
383 included publications. Individual forms will be created and used to record quantitative and
384 qualitative data (S2 Appendix. Data extraction form) extracted from quantitative, qualitative,
385 and mixed method studies. A pilot data extraction process with a draft extraction form will be
386 performed on approximately 10 articles to determine if all relevant information is being
387 captured.

388 The Cochrane Handbook will be used to provide guidance for the inclusion of cluster
389 randomised control trials in this review [23].

390 Two authors (KG and NB) will extract the data, and a third author (EA-D) will cross-check
391 the data to ensure that all relevant data has been extracted. Any disagreements between KG

392 and NB will be resolved by discussion. A third author (EA-D) will be involved to resolve any
393 outstanding disagreement as necessary.

394

395 **Dealing with missing data**

396 Study authors will be contacted via email regarding any unreported data or to seek
397 clarification on study methods. Should the data remain unavailable, the data at hand will be
398 analysed and the significance of any missing data will be discussed among authors (KG, NB
399 and EA-D). Authors will then deliberate on the most suitable method for dealing with the
400 missing data as per guidelines outlined in the Cochrane Handbook [24].

401

402 **Methodological quality assessment**

403 All included studies (quantitative, qualitative, and mixed methods) will be assessed for
404 methodological quality independently and in duplicate by two authors (KG and NB). Any
405 disagreements will be resolved by discussion or by involving a third author (EA-D) if
406 necessary.

407 **Quantitative studies**

408 To assess randomised controlled trials (RCTs) included in this review we plan to utilise the
409 Cochrane risk of bias tool (ROB-2) [25]. This tool evaluates selection, performance,
410 detection, attrition, reporting and additional sources of bias allowing us to categorise each of
411 the included studies as having low, moderate, or high risk of bias. A summary of the
412 assessment of each study with the overall judgement will be recorded and tabulated.

413 Non-randomised controlled trials (non RCTs) will be critically appraised using the
414 Newcastle-Ottawa Scale (NOS) [26]. The NOS uses a star system for each included non
415 RCT, which entails scoring stars based on a specific criterion. The overall quality of each
416 study will be interpreted based on the total number of stars awarded. A comprehensive
417 summary of all the assessments conducted, along with an overall judgement, will be recorded
418 and tabulated.

419 **Qualitative studies**

420 The Critical Appraisal Skills Programme (CASP) quality assessment tool for qualitative
421 studies will be applied to determine the rigour of qualitative methods used in included
422 studies. The CASP tool will be used to examine the quality of a study in relation to 10
423 questions about research aims, appropriateness of methodology and design, recruitment
424 strategy, data collection, researcher reflexivity, consideration of ethical issues, data analysis,
425 statement of finding and the value of the research [27].

426 **Mixed methods studies**

427 The Mixed Methods Appraisal Tool (MMAT) will be applied to assess the risk of bias for
428 mixed method studies [28]. The following criteria will be used to assess the risk of bias:

- 429 1. Is there an adequate rationale for using a mixed methods design to address the
430 research question?
- 431 2. Are the different components of the study effectively integrated to answer the
432 research question?
- 433 3. Are the outputs of the integration of qualitative and quantitative components
434 adequately addressed?
- 435 4. Are divergences and inconsistencies between quantitative and qualitative results
436 adequately addressed?

437 5. Do the different components of the study adhere to the quality criteria of each
438 tradition of the methods involved?

439

440 **Unit of analysis**

441 The unit of analysis for the quantitative component of this review will be primarily at the
442 individual level. Studies that will be selected for inclusion in this review will assess the
443 effectiveness of integrating cervical cancer prevention strategies into HIV care services in
444 improving the uptake of these strategies by AGYW living with HIV globally. Key
445 epidemiological measures such as changes in the incidence, mortality, or prevalence of
446 cervical cancer as well as utilisation of cervical cancer prevention services and rates thereof
447 will be analysed at an individual level.

448 The unit of analysis for the qualitative component will be thematic. Qualitative data from
449 included studies will be analysed to identify common themes related to the effectiveness of
450 integrating cervical cancer prevention strategies into HIV care services. Themes related to the
451 knowledge, awareness, and willingness of AGYW living with HIV to utilise these services
452 following integration will be analysed at an individual level.

453

454 **Data synthesis**

455 **Quantitative studies**

456 The findings from the included quantitative studies will be narratively summarised and
457 graphically illustrated [29]. Study results will be expressed as either numeric results or
458 measures of association, with their associated variation and confidence intervals. The

459 magnitude of heterogeneity between the included studies will then be assessed quantitatively
460 using the I^2 statistic [30]. I^2 values will be interpreted as follows: 0 to 40% might not be
461 important; 30 to 60% may represent moderate heterogeneity; 50 to 90% may represent
462 substantial heterogeneity and 75 to 100% represents considerable heterogeneity [30]. The
463 significance of heterogeneity will be determined by the p-value as outlined in the Cochrane
464 Handbook [30]. For studies with moderate to significant heterogeneity, a random effects
465 model will be used to obtain a pooled estimate of the outcome. If heterogeneity is between 0
466 to 40% a random effects model will also be used. In this instance, the random effects model
467 will account for our lack of knowledge about why real, or apparent, intervention effects differ
468 by considering the differences as if they were random [30].

469 Random effects models for meta-analysis will be performed using Review Manager software
470 (RevMan 2020, V.5.4.1). If the heterogeneity detected is significantly high, a subgroup
471 analysis will be performed to detect the possible sources [31]. A funnel plot will be used to
472 assess for publication bias using R software (R Studio version 2023.03.0+386). Asymmetric
473 distribution of the plot will indicate potential publication bias [32]. In addition, to statistically
474 confirm whether the asymmetry is significant or not the Begg and Egger's test will be
475 performed using R software, where a p-value less than 0.05 indicates asymmetry and
476 potential publication bias (R Studio version 2023.03.0+386) [32].

477 **Qualitative studies**

478 For the qualitative analysis thematic synthesis will be used to combine the findings of studies
479 that describe the knowledge, awareness, and willingness of AGYW living with HIV to utilise
480 and adhere to cervical cancer prevention strategies following integration [33]. The findings of
481 included qualitative studies will be examined against the aims of this review, recurring
482 patterns will be identified, and the qualitative data patterns will be interpreted by developing

483 a coding framework. One article that closely answers the review objectives will be selected
484 and used as a starting point to build a coding list. Two authors (KG and NB) will conduct
485 “line-by-line” coding according to the content and meaning of the relevant findings of the
486 article. The two authors (KG and NB) will subsequently discuss, with a third author (EA-D),
487 the “free” codes, develop an initial coding list, and independently test this list on two
488 additional articles to determine if and how well the concepts translate from one study to
489 another. The three authors (KG, NB and EA-D) will subsequently discuss the codes emerging
490 from the data and agree on a preliminary coding framework. The remaining studies will then
491 be coded line-by-line using the agreed coding framework, adding new codes as necessary.
492 Relevant findings, reported anywhere in the primary qualitative studies, will be coded. If new
493 codes arise during the analysis process, a discussion among the three authors will be
494 conducted (KG, NB and EA-D) and the coding list will be amended accordingly. Two
495 authors (KG and NB) will revisit articles already coded to determine if the new codes apply
496 or not. This process will continue until they have extracted data from all the included articles.
497 Data extraction will be verified by a third author (EA-D). Review findings will then be
498 synthesised from the data that have been given the same codes across the studies. Findings
499 will be shared with the third author (EA-D) to review. Finally, we will re-read the included
500 studies to check that we have extracted all data relevant to the findings.

501 **Combining quantitative and qualitative data**

502 Following the synthesis of quantitative and qualitative data independently, they will be
503 combined using the methods and suggestions provided in the Cochrane Handbook [34].
504 According to the Johanna Briggs guidelines on data synthesis and integration for mixed
505 method reviews if the research question can be addressed by quantitative and qualitative
506 research designs a convergent integrated approach will be followed [35]. However, if the

507 review aims to explore various aspects or dimensions of a particular phenomenon of interest
508 the convergent segregated approach will be followed [35].

509

510 **Sensitivity Analysis**

511 To ensure the robustness and reliability of the findings of this review a sensitivity analysis
512 will be conducted to assess the impact of the various methodological decisions on the results
513 of this review and will be performed on both quantitative and qualitative components. The
514 domains that will be considered include the quality of the included studies, sample size and
515 the meta-analysis technique applied. If results remain consistent across the different analyses,
516 the results can be considered robust as even with different decisions they remain the
517 same/similar. If the results differ across sensitivity analyses, this is an indication that the
518 result may need to be interpreted with caution [35].

519

520 **Assessment of quality of evidence**

521 **Quantitative studies**

522 The quality of evidence for primary quantitative outcomes will be evaluated using the five
523 Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria:
524 risk of bias, consistency of effect, imprecision, indirectness, and publication bias [36]. To
525 facilitate this process, we will utilize GRADEpro GDT software and include footnotes to
526 elucidate any determinations made to downgrade the quality of evidence. We will use the
527 study design of each included study as a determining factor of whether to upgrade (i.e.
528 observational studies) or downgrade (i.e. RCTs) the quality of evidence.

529 An assessment of each outcome will be presented in a GRADE Evidence Profile. Two
530 authors (KG and NB) will detail the number of studies, the number of participants, and the
531 numerical result of the meta-analysis for each outcome. The effects of interventions on the
532 outcomes included in the GRADE Evidence Profiles will be interpreted according to
533 magnitude of effect and certainty of the evidence, using GRADE guidance on informative
534 statements to combine size and certainty of an effect [36]. If meta-analysis is unsuitable or
535 units of analysis are incomparable, results will be presented in a narrative 'Summary of
536 findings' table format, with a recognition of the imprecision in evidence due to the absence of
537 a quantitative effect measure [37]. This process will be reviewed by a third author (EA-D).

538 **Qualitative studies**

539 To evaluate the confidence in synthesized qualitative findings, the Grades of
540 Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence
541 from Qualitative Reviews (CERQual) approach will be used [38]. This approach
542 encompasses four key domains: methodological limitations, relevance of contributing studies
543 to the research question, coherence of study findings, and adequacy of data supporting the
544 study findings. For each outcome, two authors (KG and NB) will consolidate the findings
545 from these four domains and offer rationale to elucidate any determinations made to
546 downgrade the quality of evidence. This process will be reviewed by a third author (EA-D).

547

548 **Discussion**

549 This review aims to address a critical gap in the existing literature by proposing a
550 comprehensive mixed-methods systematic review on the effectiveness of integrating cervical
551 cancer prevention strategies into HIV care programs. The dual burden of cervical cancer and

552 HIV presents a significant public health challenge, especially in resource-limited settings,
553 where both conditions are prevalent. There is a need to develop effective and integrated
554 approaches that comprehensively address these dual health concerns simultaneously among
555 AGYW living with HIV. The proposed research design, a mixed-methods systematic review,
556 is well-suited to capture both quantitative effectiveness measures and qualitative insights into
557 the knowledge, awareness, and willingness of AGYW living with HIV. By incorporating
558 vaccination, screening, pre-treatment and educational interventions into the assessment
559 framework, this review aims to provide a holistic understanding of the potential benefits
560 derived from the integration of prevention strategies. The strength of this review is the
561 inclusion of current and up-to-date literature. Existing studies focus on isolated elements
562 resulting in a fragmented understanding. The global search covering multiple databases
563 enhances the robustness and reliability of this review.

564

565 **Conclusion**

566 The anticipated outcomes of this systematic review could inform and improve
567 implementation of current comprehensive cervical cancer prevention guidelines
568 recommended by the WHO. Ultimately effective integration not only aligns with a holistic
569 approach to women's health but also contributes substantially towards improving health
570 outcomes for AGYW living with HIV. Reducing cervical cancer incidence and mortality can
571 make a meaningful impact on global public health, thus emphasizing the importance of this
572 systematic review.

573

574

575 **Ethics**

576 Ethics approval will not be required for this review as the work constitutes a secondary
577 analysis of published research, which is already available in the public domain.

578

579 **Research to practice**

580 The review team anticipates that the findings from this proposed systematic review will
581 enhance equitable access to cervical cancer prevention services, thereby promoting the
582 quality of life for AGYW living with HIV.

583 **Author contributions**

584 **Conceptualization:** KG, NB and EA-D

585 **Methodology:** KG, SN, NB and EA-D

586 **Formal analysis:** KG, NB and EA-D

587 **Data curation:** KG and SN

588 **Writing (original draft and preparation):** KG

589 **Writing (review and editing):** SN, NB and EA-D

590 **Visualization:** KG, NB and EA-D

591 **Supervision:** NB and EA-D

592 **Project administration:** KG

593

594 **References**

- 595 1. Cervical cancer. [cited 26 May 2024]. Available: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/cervical-cancer)
596 [sheets/detail/cervical-cancer](https://www.who.int/news-room/fact-sheets/detail/cervical-cancer)
- 597 2. Okunade KS. Human papillomavirus and cervical cancer. *J Obstet Gynaecol.* 2020;40:
598 602–608. doi:10.1080/01443615.2019.1634030
- 599 3. Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical
600 cancer therapies: Current challenges and future perspectives. *Tumour Virus Res.*
601 2022;13: 200238. doi:10.1016/j.tvr.2022.200238
- 602 4. Williamson A-L. Recent Developments in Human Papillomavirus (HPV) Vaccinology.
603 *Viruses.* 2023;15: 1440. doi:10.3390/v15071440
- 604 5. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al.
605 Estimates of the global burden of cervical cancer associated with HIV. *Lancet Glob*
606 *Health.* 2021;9: e161–e169. doi:10.1016/S2214-109X(20)30459-9
- 607 6. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical
608 cancer prevention. Second edition. Geneva: World Health Organization; 2021.
- 609 7. Human papillomavirus (HPV). [cited 26 May 2024]. Available:
610 [https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-](https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV))
611 [papillomavirus-vaccines-\(HPV\)](https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV))
- 612 8. Zhang M, Sit JWH, Chan DNS, Akingbade O, Chan CWH. Educational Interventions to
613 Promote Cervical Cancer Screening among Rural Populations: A Systematic Review.
614 *Int J Environ Res Public Health.* 2022;19: 6874. doi:10.3390/ijerph19116874
- 615 9. Banerjee D, Mittal S, Mandal R, Basu P. Screening technologies for cervical cancer:
616 Overview. *CytoJournal.* 2022;19: 23. doi:10.25259/CMAS_03_04_2021
- 617 10. Castle PE, Einstein MH, Sahasrabudhe VV. Cervical cancer prevention and control in
618 women living with human immunodeficiency virus. *CA Cancer J Clin.* 2021;71: 505–
619 526. doi:10.3322/caac.21696
- 620 11. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global
621 estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of
622 the WHO Global Cervical Cancer Elimination Initiative. *Lancet Glob Health.* 2023;11:
623 e197–e206. doi:10.1016/S2214-109X(22)00501-0
- 624 12. Kakotkin VV, Semina EV, Zadorkina TG, Agapov MA. Prevention Strategies and Early
625 Diagnosis of Cervical Cancer: Current State and Prospects. *Diagnostics.* 2023;13: 610.
626 doi:10.3390/diagnostics13040610
- 627 13. Sigfrid L, Murphy G, Haldane V, Chuah FLH, Ong SE, Cervero-Liceras F, et al.
628 Integrating cervical cancer with HIV healthcare services: A systematic review.
629 Consolaro MEL, editor. *PLOS ONE.* 2017;12: e0181156.
630 doi:10.1371/journal.pone.0181156

- 631 14. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwasha C,
632 Mkumba G, et al. Advancing Cervical Cancer Prevention Initiatives in Resource-
633 Constrained Settings: Insights from the Cervical Cancer Prevention Program in Zambia.
634 PLoS Med. 2011;8: e1001032. doi:10.1371/journal.pmed.1001032
- 635 15. Huchko MJ, Bukusi EA, Cohen CR. Building capacity for cervical cancer screening in
636 outpatient HIV clinics in the Nyanza province of western Kenya. *Int J Gynecol Obstet*.
637 2011;114: 106–110. doi:10.1016/j.ijgo.2011.02.009
- 638 16. Moon TD, Silva Matos C, Cordoso A, Baptista AJ, Sidat M, Vermund SH.
639 Implementation of cervical cancer screening using visual inspection with acetic acid in
640 rural Mozambique: successes and challenges using HIV care and treatment programme
641 investments in Zambézia Province. *J Int AIDS Soc*. 2012;15: 17406.
642 doi:10.7448/IAS.15.2.17406
- 643 17. Ramogola-Masire D, De Klerk R, Monare B, Ratshaa B, Friedman HM, Zetola NM.
644 Cervical Cancer Prevention in HIV-Infected Women Using the “See and Treat”
645 Approach in Botswana. *JAIDS J Acquir Immune Defic Syndr*. 2012;59: 308–313.
646 doi:10.1097/QAI.0b013e3182426227
- 647 18. Lizarondo L, Stern C, Carrier J, Godfrey C, Rieger K, Salmond S, et al. Mixed methods
648 systematic reviews. In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors.
649 *JBI Manual for Evidence Synthesis*. JBI; 2024. doi:10.46658/JBIMES-24-07
- 650 19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
651 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*.
652 2021; n71. doi:10.1136/bmj.n71
- 653 20. PRISMA-P Group, Moher D, Shamseer L, Clarke M, Gherzi D, Liberati A, et al.
654 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-
655 P) 2015 statement. *Syst Rev*. 2015;4: 1. doi:10.1186/2046-4053-4-1
- 656 21. Zotero | Downloads. [cited 29 May 2024]. Available: <https://www.zotero.org/download/>
- 657 22. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile
658 app for systematic reviews. *Syst Rev*. 2016;5: 210. doi:10.1186/s13643-016-0384-4
- 659 23. Higgins JPT, Eldridge S, Li T. Chapter 23: Including variants on randomized trials.
660 *Cochrane Handbook for Systematic Reviews of Interventions* version 64. Available:
661 <https://training.cochrane.org/handbook/current/chapter-23>
- 662 24. Deeks JJ, Higgins JPT, Altman DG. Chapter 10.12: Analysing data and undertaking
663 meta-analyses: Missing data. *Cochrane Handbook for Systematic Reviews of*
664 *Interventions* version 6.4. Available:
665 <https://training.cochrane.org/handbook/current/chapter-10>
- 666 25. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
667 revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019; 14898.
668 doi:10.1136/bmj.14898

- 669 26. Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Losos M, et al. The Newcastle-
670 Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-
671 Analysis.
- 672 27. Long HA, French DP, Brooks JM. Optimising the value of the critical appraisal skills
673 programme (CASP) tool for quality appraisal in qualitative evidence synthesis. *Res*
674 *Methods Med Health Sci.* 2020;1: 31–42. doi:10.1177/2632084320947559
- 675 28. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed
676 Methods Appraisal Tool (MMAT) version 2018 for information professionals and
677 researchers. *Educ Inf.* 2018;34: 285–291. doi:10.3233/EFI-180221
- 678 29. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the
679 Conduct of Narrative Synthesis in Systematic Reviews.
- 680 30. Deeks JJ, Higgins JPT, Altman DG. Chapter 10.10: Analysing data and undertaking
681 meta-analyses: Heterogeneity. *Cochrane Handbook for Systematic Reviews of*
682 *Interventions* version 6.4. Available:
683 <https://training.cochrane.org/handbook/current/chapter-10>
- 684 31. Deeks JJ, Higgins JPT, Altman DG. Chapter 10.11: Analysing data and undertaking
685 meta-analyses: Investigating heterogeneity. *Cochrane Handbook for Systematic*
686 *Reviews of Interventions* version 6.4. Available:
687 <https://training.cochrane.org/handbook/current/chapter-10>
- 688 32. Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A
689 step by step guide for conducting a systematic review and meta-analysis with simulation
690 data. *Trop Med Health.* 2019;47: 46. doi:10.1186/s41182-019-0165-6
- 691 33. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in
692 systematic reviews. *BMC Med Res Methodol.* 2008;8: 45. doi:10.1186/1471-2288-8-45
- 693 34. Flemming K, Booth A, Hannes K, Cargo M, Noyes J. *Cochrane Qualitative and*
694 *Implementation Methods Group guidance series—paper 6: reporting guidelines for*
695 *qualitative, implementation, and process evaluation evidence syntheses.* *J Clin*
696 *Epidemiol.* 2018;97: 79–85. doi:10.1016/j.jclinepi.2017.10.022
- 697 35. Aromataris E, Munn Z. *JBI manual for evidence synthesis.* Adelaide, Australia: Joanna
698 Briggs Institute; 2020.
- 699 36. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines
700 26: informative statements to communicate the findings of systematic reviews of
701 interventions. *J Clin Epidemiol.* 2020;119: 126–135. doi:10.1016/j.jclinepi.2019.10.014
- 702 37. Chan RJ, Webster J, Marquart L. Information interventions for orienting patients and
703 their carers to cancer care facilities. *Cochrane Consumers and Communication Group,*
704 *editor. Cochrane Database Syst Rev.* 2011 [cited 26 May 2024].
705 doi:10.1002/14651858.CD008273.pub2
- 706 38. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gülmezoglu M, et al.
707 Using Qualitative Evidence in Decision Making for Health and Social Interventions: An
708 Approach to Assess Confidence in Findings from Qualitative Evidence Syntheses

709 (GRADE-CERQual). PLOS Med. 2015;12: e1001895.
710 doi:10.1371/journal.pmed.1001895

711

712 **Supporting information**

713

714 S1 Checklist. PRISMA-P 2015 checklist.

715 S1 Appendix. Database literature search strategy.

716 S2 Appendix. Data extraction form.

PROPHYLACTIC HPV VACCINATION

Females living without HIV

9-20 years: 1 or 2 dose schedule


21 years and older: 2 dose schedule with a 6 month interval

Females living with HIV

All ages: minimum 2 dose schedule or 3 dose if feasible

EDUCATION

- Health promotion and education of cervical cancer risks and prevention strategies
- Sexual and reproductive education



CERVICAL CANCER SCREENING

Females living without HIV

(30-49 year olds regarded as the priority age group, screened every 5-10 years)

HPV DNA testing, VIA, Pap smear

Females living with HIV

(25-49 year olds regarded as the priority age group, screened every 3-5 years)

HPV DNA testing

TREATMENT OF PRECANCEROUS LESIONS

Females living without HIV

Excision and ablation techniques

Females living with HIV

Excision techniques

- Surgery
- Radiotherapy
- Chemotherapy
- Palliative care